Research Supporting a Pilot Study of Metronomic Dapsone during Glioblastoma Chemoirradiation

Med Sci (Basel). 2021 Feb 16;9(1):12. doi: 10.3390/medsci9010012.

Abstract

This short note presents previous research data supporting a pilot study of metronomic dapsone during the entire course of glioblastoma treatment. The reviewed data indicate that neutrophils are an integral part of human glioblastoma pathophysiology, contributing to or facilitating glioblastoma growth and treatment resistance. Neutrophils collect within glioblastoma by chemotaxis along several chemokine/cytokine gradients, prominently among which is interleukin-8. Old data from dermatology research has shown that the old and inexpensive generic drug dapsone inhibits neutrophils' chemotaxis along interleukin-8 gradients. It is on that basis that dapsone is used to treat neutrophilic dermatoses, for example, dermatitis herpetiformis, bullous pemphigoid, erlotinib-related rash, and others. The hypothesis of this paper is that dapsone will reduce glioblastomas' neutrophil accumulations by the same mechanisms by which it reduces dermal neutrophil accumulations in the neutrophilic dermatoses. Dapsone would thereby reduce neutrophils' contributions to glioblastoma growth. Dapsone is not an ideal drug, however. It generates methemoglobinemia that occasionally is symptomatic. This generation is reduced by concomitant use of the antacid drug cimetidine. Given the uniform lethality of glioblastoma as of 2020, the risks of dapsone 100 mg twice daily and cimetidine 400 mg twice daily is low enough to warrant a judicious pilot study.

Keywords: dapsone; edema; glioblastoma; interleukin-8; myeloid derived suppressor cells; neutrophils.

MeSH terms

  • Cimetidine
  • Dapsone / therapeutic use*
  • Glioblastoma* / drug therapy
  • Humans
  • Interleukin-8
  • Pemphigoid, Bullous
  • Pharmaceutical Preparations
  • Pilot Projects

Substances

  • Interleukin-8
  • Pharmaceutical Preparations
  • Cimetidine
  • Dapsone